16.5 Million Patients Worldwide are Remotely Monitored
December 17, 2018 | Berg InsightEstimated reading time: 1 minute
The number of remotely monitored patients grew by 41% to 16.5 million in 2017 as the market acceptance continues to grow in several key verticals. This number includes all patients enrolled in mHealth care programs in which connected medical devices are used as a part of the care regimen. Connected medical devices used for various forms of personal health tracking are not included in this figure. Berg Insight estimates that the number of remotely monitored patients will grow at a compound annual growth rate (CAGR) of 31.0% to reach 83.4 million by 2023.
The two main applications are monitoring of patients with sleep therapy devices and monitoring of patients with implantable cardiac rhythm management (CRM) devices. These two segments accounted for 82% of all connected home medical monitoring systems in 2017. The number of remotely monitored sleep therapy patients grew by 37% in 2017, mainly driven by Philips and ResMed that together dominate the sleep therapy market. The CRM market is led by companies such as Medtronic, Boston Scientific and Abbott that started to include connectivity in CRM solutions more than a decade ago. Telehealth is the third largest segment with 0.8 million connections at the end of the year. Leading telehealth hub vendors include Tunstall Healthcare, Resideo (Honeywell), Medtronic, Philips and Qualcomm Life. Other device categories—including ECG, glucose level, medication compliance, blood pressure monitors and others—accounted for just over two million connections. “The most promising segment is medication compliance, which we expect will become the second most connected segment in the next five years”, says Sebastian Hellström, IoT Analyst at Berg Insight.
More than 60% of all connected medical monitoring devices rely on cellular connectivity today and has become the de-facto standard for most types of connected home medical monitoring devices. The number of mHealth devices with integrated cellular connectivity increased from 7.1 million in 2016 to 10.7 million in 2017. The use of BYOD connectivity will increase the most during the next six years, with a forecasted CAGR of 48.2%. “BYOD involves low cost and the technology is mostly adopted in patient-centric therapeutic areas such as diabetes and asthma that have younger patient demographics compared to many other chronic diseases. Many of these patients prefer to use their own smartphone as the interface instead of carrying around a dedicated device for remote monitoring”, concluded Hellström.
Suggested Items
Mycronic Releases Interim Report January–March 2024
04/18/2024 | MycronicNet sales increased 39 percent to SEK 1,692 (1,219) million. Based on constant exchange rates, net sales increased 42 percent.
Aspocomp’s Q1 Net Sales and Operating Result Decreased YoY
04/18/2024 | AspocompInflation and interest rates, weak economic development, the uncertainties posed by Russia’s war of aggression and the situation in the Middle East, and global trade policy tensions will affect the operating environment of Aspocomp and its customers in the 2024 fiscal year.
Cicor Records Solid Growth in Q1
04/16/2024 | CicorThe Cicor Group continued to grow in the first three months of the year. Quarterly sales increased by 11.8% to CHF 107.3 million compared to the first quarter of the previous year (Q1/2023: CHF 96.0 million).
Europe’s IT, Business Services Sector on the Rebound in Q1: ISG Index
04/15/2024 | BUSINESS WIREEurope’s demand for IT and business services in the first quarter rose for the first time in a year, powered by growth from the banking, financial services and insurance (BFSI) sector, according to the latest state-of-the-industry report from Information Services Group (ISG), a leading global technology research and advisory firm.
FTG Announces Q1 2024 Financial Results
04/12/2024 | Firan Technology Group CorporationDuring Q1 2024, the Corporation has continued to invest in technology in existing sites, grow the business organically, and integrate the two acquisitions completed last year. FTG is strategically deploying its capital in ways that will drive increased shareholder returns for the future in both the near term and long term. Specifically, FTG accomplished the following in Q1 2024, which continues to improve the Corporation and position it for the future: